TimesSquare Capital Management LLC Boosts Holdings in Merus (NASDAQ:MRUS)

TimesSquare Capital Management LLC boosted its position in Merus (NASDAQ:MRUS) by 21.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 331,195 shares of the biotechnology company’s stock after purchasing an additional 58,760 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Merus were worth $13,927,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Gordian Capital Singapore Pte Ltd increased its holdings in shares of Merus by 10.4% in the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock worth $250,000 after buying an additional 470 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after buying an additional 489 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Merus by 2.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 43,208 shares of the biotechnology company’s stock worth $1,817,000 after buying an additional 921 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Merus by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,517 shares of the biotechnology company’s stock worth $610,000 after buying an additional 1,398 shares during the last quarter. Finally, Avior Wealth Management LLC bought a new position in shares of Merus in the 4th quarter worth $76,000. Institutional investors own 96.14% of the company’s stock.

Merus Stock Up 6.6 %

Shares of Merus stock opened at $45.07 on Thursday. The firm has a market cap of $3.09 billion, a PE ratio of -11.41 and a beta of 1.11. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The company’s fifty day simple moving average is $41.51 and its two-hundred day simple moving average is $46.96.

Analyst Ratings Changes

A number of equities analysts have recently commented on MRUS shares. Piper Sandler started coverage on shares of Merus in a report on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Merus in a report on Thursday, November 21st. They set a “buy” rating and a $73.00 target price on the stock. Citigroup increased their target price on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a report on Monday, December 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 target price on shares of Merus in a report on Monday, December 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $85.00 target price on shares of Merus in a report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $85.92.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.